ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:44:39 2024-04-16 am EDT 5-day change 1st Jan Change
0.163 USD -0.91% Intraday chart for ReShape Lifesciences Inc. -7.14% -35.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Big Banks Kick -2- DJ
Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certain Restricted Stock Units of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024. CI
Certain Warrants of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024. CI
Certain Options of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024. CI
Certain Common Stock of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024. CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex CI
Top Midday Gainers MT
North American Morning Briefing : Traders Await FOMC, Powell DJ
ReShape Lifesciences Gets FDA Approval for PMA Supplement Used in Latest Lap-Band DJ
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX CI
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023 CI
Transcript : ReShape Lifesciences Inc., Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M MT
Sector Update: Health Care Stocks Lower Late Afternoon MT
Sector Update: Health Care Stocks Declining Friday Afternoon MT
ReShape Lifesciences Prices $3 Million Offering at $0.33 Per Unit MT
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System CI
ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device CI
Transcript : ReShape Lifesciences Inc., Q2 2023 Earnings Call, Aug 07, 2023
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q2 Revenue $2.3M, vs. Street Est of $2.6M MT
Chart ReShape Lifesciences Inc.
More charts
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1645 USD
Average target price
1 USD
Spread / Average Target
+507.94%
Consensus
  1. Stock Market
  2. Equities
  3. RSLS Stock
  4. News ReShape Lifesciences Inc.
  5. ReShape Lifesciences : Alliance Global Partners Adjusts ReShape Lifesciences PT to $13.75 From $18.50, Maintains Buy Rating